Proton-Based Radiation Therapy for Skull Base Chondrosarcomas in Children and Adolescents: 40-Year Experience From the Massachusetts General Hospital

被引：0

作者：

Ioakeim-Ioannidou, Myrsini ^{[1
,5
]}

Goldberg, Saveli ^{[1
]}

Urell, Tobias ^{[1
]}

Tejada, Athena ^{[1
]}

Nielsen, G. Petur ^{[3
]}

Hung, Yin P. ^{[3
]}

Adams, Judith ^{[1
]}

Fullerton, Barbara ^{[1
]}

Caruso, Paul ^{[4
]}

Patino, Manuel ^{[2
]}

Buch, Karen ^{[2
]}

Rincon, Sandra ^{[2
]}

Sakai, Osamu ^{[2
]}

Tolia, Maria ^{[5
]}

Ebb, David ^{[6
]}

Cote, Gregory ^{[7
]}

Curry, William ^{[8
]}

Giantsoudi, Drosoula ^{[1
]}

Macdonald, Shannon M. ^{[1
]}

机构：

[1] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02115 USA

[2] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA

[3] Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA

[4] Lenox Hill Radiol & Med Imaging Associates, Deparment Neuroradiol, New York, NY USA

[5] Univ Crete, Sch Med, Dept Radiotherapy, Iraklion, Greece

[6] Massachusetts Gen Hosp, Dept Pediat Hematol Oncol, Boston, MA USA

[7] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA USA

[8] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA USA

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2025年 / 121卷 / 02期

关键词：

CLASSIFICATION; RADIOTHERAPY; CHORDOMA; TUMORS; BONE;

D O I：

10.1016/j.ijrobp.2024.09.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: The literature on skull base chondrosarcoma (CHS) is scarce. We report outcomes for pediatric and young patients <= 22 years with base of skull CHSs treated with proton-based radiation therapy (PBRT). Methods and Materials: We retrospectively reviewed all patients treated with PBRT between 1981 and 2023. Primary endpoints were overall survival (OS), chondrosarcoma-specific survival (CSS), progression-free survival (PFS), local control, and distal control. Results: Eighty-four patients were identified. Median age at diagnosis was 19 years (range, 6-22). Most patients (n = 79, 94%) had conventional CHS, whereas 5 (6%) had mesenchymal CHS. Nine patients (11%) underwent gross total resection, 64 (76%) subtotal resection, and 11 patients (13%) underwent biopsy. Twenty-four (29%) patients progressed before radiation therapy. The median prescription dose was 70 Gy (relative biological equivalent) (range, 50-79.7). At a median follow-up of 18.0 years (IQR, 9.2-26.2) from diagnosis, 11 patients recurred (7 local, 4 distant). Six patients died of disease. Five patients died of other causes. Ten-year OS, CSS, and PFS rates for all patients were 93.3%, 94.7%, and 88%, respectively. Twenty-year OS, CSS, and PFS rates for conventional CHS (n = 79) were 93.1%, 97.1%, and 89.2%, respectively. Mesenchymal histology was significantly associated with worse OS and PFS. Preradiation therapy tumor progression portended worse OS and CSS. Eight patients (9.9 %) experienced a late toxicity grade 3 or greater. Conclusions: This is the largest cohort of pediatric base of skull CHSs in literature to date. High-dose PBRT after surgical resection achieves excellent disease control with minimal toxicity. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

引用

页码：403 / 413

页数：11

共 30 条

[1] Dibas M., Doheim M.F., Ghozy S., Ros M.H., El-Helw G.O., Reda A., Incidence and survival rates and trends of skull Base chondrosarcoma: a population-based study, Clin Neurol Neurosurg, 198, (2020)
[2] Bloch O.G., Jian B.J., Yang I., Et al., A systematic review of intracranial chondrosarcoma and survival, J Clin Neurosci, 16, pp. 1547-1551, (2009)
[3] Almefty K., Pravdenkova S., Colli B.O., Al-Mefty O., Gokden M., Chordoma and chondrosarcoma: similar, but quite different, skull base tumors, Cancer, 110, pp. 2457-2467, (2007)
[4] Rosenberg A.E., Nielsen G.P., Keel S.B., Et al., Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma, Am J Surg Pathol, 23, pp. 1370-1378, (1999)
[5] Varma D.G., Ayala A.G., Carrasco C.H., Guo S.Q., Kumar R., Edeiken J., Chondrosarcoma: MR imaging with pathologic correlation, RadioGraphics, 12, pp. 687-704, (1992)
[6] Verdegaal S.H.M., Bovee J.V.M.G., Pansuriya T.C., Et al., Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients, Oncologist, 16, pp. 1771-1779, (2011)
[7] Choi J.H., Ro J.Y., The 2020 WHO classification of tumors of bone: an updated review, Adv Anat Pathol, 28, pp. 119-138, (2021)
[8] Dorfman H.D., Czerniak B., Bone cancers, Cancer, 75, pp. 203-210, (1995)
[9] Aigner T., Towards a new understanding and classification of chondrogenic neoplasias of the skeleton–biochemistry and cell biology of chondrosarcoma and its variants, Virchows Arch, 441, pp. 219-230, (2002)
[10] Hogendoorn P.C.W., Athanasou N., Bielack S., Et al., Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 21, pp. v204-v213, (2010)

← 1 2 3 →